A phase II single-arm study of the FGFR inhibitor pemigatinib in patients with metastatic colorectal cancer (mCRC) harboring FGF/FGFR alterations.

被引：0
|
作者：
Ciombor, Kristen Keon
Zemla, Tyler J.
Hubbard, Joleen M.
Jia, Jingquan
Gbolahan, Olumide B.
Sousa, Andrea
Wilson, Luke
Waechter, Blake
Ou, Fang-Shu
Nixon, Andrew B.
Bekaii-Saab, Tanios S.
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] Mayo Clin, Alliance Stat & Data Management Ctr, Rochester, MN USA
[3] Mayo Clin, Rochester, MN USA
[4] Duke Univ, Med Ctr, Durham, NC USA
[5] Emory Univ, Sch Med, Atlanta, GA USA
[6] Mayo Clin, Canc Ctr Scottsdale, Phoenix, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
139
引用
收藏
页码：139 / 139
页数：1
相关论文
共 50 条
  • [1] A phase II telemedicine study of pemigatinib in adult patients with unresectable or metastatic pancreas cancer with FGFR2 gene fusions or other FGFR genetic alterations.
    Risch, Zachary
    Wing, Michele
    Reeser, Julie
    Stein, Leah
    Dao, Thuy
    Smith, Amy
    Samorodnitsky, Eric
    Paruchuri, Anoosha
    Pan, Xueliang Jeff
    Roychowdhury, Sameek
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS717 - TPS717
  • [2] A phase II study of JNJ-42756493, a pan-FGFR tyrosine kinase inhibitor, in patients with metastatic or unresectable urothelial cancer (UC) harboring FGFR gene alterations
    Siefker-Radtke, Arlene O.
    Mellado, Begona
    Decaestecker, Karel
    Burke, John M.
    O'Hagan, Anne
    Avadhani, Anjali
    Zhong, Bob
    Santiago-Walker, Ademi
    De Porre, Peter
    Brookman-May, Sabine
    Garcia-Donas, Jesus
    CANCER RESEARCH, 2016, 76
  • [3] Phase I result of ICP-192 (gunagratinib), a highly selective irreversible FGFR inhibitor, in patients with advanced solid tumors harboring FGFR pathway alterations.
    Guo, Ye
    Yuan, Chunwang
    Ying, Jieer
    Zhu, Xu
    Luan, Guodong
    Zhang, Bin
    Zhao, Renbin
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer
    Chen, Xiaofeng
    Qiu, Tianzhu
    Zhu, Yingwei
    Sun, Jing
    Li, Ping
    Wang, Biao
    Lin, Peinan
    Cai, Xiaomin
    Han, Xiao
    Zhao, Fengjiao
    Shu, Yongqian
    Chang, Lianpeng
    Jiang, Hua
    Gu, Yanhong
    ONCOLOGIST, 2019, 24 (07): : 883 - +
  • [5] Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
    Pant, Shubham
    Schuler, Martin
    Iyer, Gopa
    Witt, Olaf
    Doi, Toshihiko
    Qin, Shukui
    Tabernero, Josep
    Reardon, Davida A.
    Massard, Christophe
    Minchom, Anna
    Lugowska, Iwona
    Carranza, Omar
    Arnold, Dirk
    Gutierrez, Martin
    Winter, Helen
    Stuyckens, Kim
    Crow, Lauren
    Najmi, Saltanat
    Hammond, Constance
    Thomas, Shibu
    Santiago-Walker, Ademi
    Triantos, Spyros
    Sweiti, Hussein
    Loriot, Yohann
    LANCET ONCOLOGY, 2023, 24 (08): : 925 - 935
  • [6] A phase 2 study of JNJ-42756493, a pan-FGFR tyrosine kinase inhibitor, in patients (pts) with metastatic or unresectable urothelial cancer (UC) harboring FGFR gene alterations
    Siefker-Radtke, Arlene O.
    Mellado, Begona
    Decaestecker, Karel
    Burke, John M.
    O'Hagan, Anne
    Avadhani, Anjali Narayan
    Zhong, Bob
    Santiago-Walker, Ademi E.
    De Porre, Peter
    Brookman-May, Sabine
    Garcia-Donas, Jesus
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies
    Subbiah, V
    Iannotti, N. O.
    Gutierrez, M.
    Smith, D. C.
    Feliz, L.
    Lihou, C. F.
    Tian, C.
    Silverman, I. M.
    Ji, T.
    Saleh, M.
    ANNALS OF ONCOLOGY, 2022, 33 (05) : 522 - 533
  • [8] A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial
    Merz, Valeria
    Zecchetto, Camilla
    Simionato, Francesca
    Cavaliere, Alessandro
    Casalino, Simona
    Pavarana, Michele
    Giacopuzzi, Simone
    Bencivenga, Maria
    Tomezzoli, Anna
    Santoro, Raffaela
    Fedele, Vita
    Contarelli, Serena
    Rossi, Irene
    Giacomazzi, Serena
    Pasquato, Martina
    Piazzola, Cristiana
    Milleri, Stefano
    de Manzoni, Giovanni
    Melisi, Davide
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [9] Discovery of CH5183284/Debio 1347, an FGFR inhibitor and phase I results in patients harboring FGFR genetic alterations
    Nakanishi, Yoshito
    CANCER SCIENCE, 2018, 109 : 151 - 151
  • [10] PRIMARY ANALYSIS OF A PHASE II, SINGLE-ARM STUDY (20060314) COMBINING PANITUMUMAB WITH FOLFIRI IN THE FIRST LINE TREATMENT OF PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Koehne, C. H.
    Mineur, L.
    Greil, R.
    Letocha, H.
    Thaler, J.
    Hofheinz, R.
    Fernebro, E.
    Gamelin, E.
    Wright, L.
    Karthaus, M.
    ANNALS OF ONCOLOGY, 2010, 21 : I51 - I51
12345